Newswise \u2014 CARLSBAD, Calif., July 27, 2026 \u2014 Pictor Holdings Inc., a global targeted proteomic platform company, today announced the public debut of its next-generation high-resolution platform at ADLM 2026, highlighted by the introduction of the new PictImager\u00ae. Designed to support scalable targeted protein analysis in research laboratories, the platform integrates Pictor’s PictArray\u00ae, PictImager\u00ae, and simplified Pictorial\u00a9 software into a streamlined workflow built around standard 96-well laboratory formats.<\/p>\n
The introduction marks an important commercialization milestone for Pictor as the company begins beta-site engagement ahead of a planned full commercial launch later this year.<\/p>\n
Targeted protein analysis is gaining momentum across translational research, biomarker discovery, and drug development. Adoption, however, remains constrained by workflow, specialized instrumentation, cost, and complexity. Pictor’s platform is designed to address those barriers through compact instrumentation, targeted assay capability, and software-enabled analysis in a familiar 96-well format.<\/p>\n
The new PictImager builds on earlier Pictor imaging systems that were developed primarily for research and technology development. The updated instrument incorporates enhanced design for improved usability and improved imaging capability, and a more robust architecture intended to support beta-site evaluation and broader commercial deployment.<\/p>\n
Together, PictArray\u00ae, PictImager\u00ae, and Pictorial\u00a9 form Pictor’s integrated targeted proteomic platform, designed to streamline targeted protein analysis from assay through results.<\/p>\n
The platform supports multiple sample types across research applications, including serum, plasma, saliva, milk, cerebrospinal fluid, and nasal swabs.<\/p>\n
Jamie Platt, PhD, CEO and Co-founder, Pictor Holdings Inc.<\/p>\n
\u201cOur goal has always been to make targeted protein analysis practical for more laboratories. The new PictImager\u00ae is an important milestone in that strategy, bringing improved imaging capability into a workflow designed for scalable targeted analysis. ADLM is the right setting to introduce the platform as we begin beta-site engagement and move toward broader commercial launch.\u201d<\/p>\n
Pictor is also advancing its Pictorial\u00a9 software to support automated image analysis, signal extraction, and workflow reporting across the integrated platform.<\/p>\n
Janine McMurdie, Chief Commercial Officer, Pictor Holdings Inc.<\/p>\n
\u201cFor labs, adoption comes down to workflow fit, reliability, and economics, not just technical capability. The new PictImager\u00ae was built around that reality: practical for everyday lab operations, personalized to the panel and workflow, and plug-and-play for easier deployment. That matters because scalable adoption requires technology that fits how labs actually work.\u201d<\/p>\n
The introduction of the new PictImager\u00ae follows the recent publication of peer-reviewed research in the Journal of Immunological Methods demonstrating the performance of Pictor’s targeted proteomic assay for extractable nuclear antigens in autoimmune disease research compared with established commercial testing platforms (DOI: 10.1016\/j.jim.2026.114087).<\/p>\n
The integrated platform is designed to support research applications including biomarker research, translational research, immune profiling, oncology research, vaccine response, and longitudinal biomarker monitoring.<\/p>\n
ADLM attendees will be the first to experience the new PictImager\u00ae as part of Pictor’s integrated targeted proteomic workflow during live demonstrations at Booth 925.<\/p>\n
Platform Highlights<\/p>\n
Up to 20 analytes per well in a standard 96-well format96 samples per runPlate read in under 1 minute; complete workflow in under 2 hoursCompatible sample types: serum, plasma, saliva, CSF, nasal swabs, milkADLM Booth 925, Anaheim Convention Center, July 26\u201330, 2026<\/p>\n
Note to Editors<\/p>\n
The new PictImager\u00ae is for Research Use Only (RUO). Pictor is beginning beta-site engagement at ADLM; full commercial launch is planned for later in 2026.<\/p>\n
About Pictor Holdings Inc.<\/p>\n
Pictor Holdings Inc. is a global targeted proteomic platform company founded in New Zealand and headquartered in Carlsbad, California, with laboratory and commercial operations in New Zealand, Australia, and India. The company develops multi-analyte proteomic assay solutions for human and animal health research environments, enabling laboratories and biopharma partners to run more analytes, faster, at lower cost. Pictor’s integrated platform includes PictArray\u00ae, PictImager\u00ae, and Pictorial\u00a9 software for research applications across human and animal health. Pictor’s IP portfolio includes 16 patents, five pending, and seven registered trademarks. For more information, visit www.pictorproteomics.com.<\/p>\n
Media Contact<\/p>\n
Kelly Krueger<\/p>\n
Audacity Health on behalf of Pictor Holdings Inc.<\/p>\n
415-235-5031<\/p>\n